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The concept of nierlianicall~ conipr ing the ventrirles 
of a failing heart into a sy stolic cwnfiguration followed 
I)! pa5sive or mechanicall\. assisted diastole is not new. 
4 variety of bellows. wrap-around devices, antl cups 
have lteen prOl~’5t3etl t o  angment forward cardiac flow 
after cardiac arrest. For example, 27 patents have Iieen 
issued in the United States alone for a Fariety of such 
tlevices 1)eginning as  early as 1936. 
Although seemingly simple antl elegant , no one has 
yet to qufficiently stud) and refine this concept to 
pi-oduce an accepted. commercially available means to 
support the failing circulation. In fact, the overwhelm- 
ing majority of patents issued were for totally unas- 
semhled antl untested devices. 
Direct mechanical ventricular actuation (DMVA), as de- 
eloped to date in our laboratory, is the only non-hlood- 
contacting means to achieve rapid, biventricular circu- 
latory support.’ l’ D y n amic cardiomyoplasty using 
blood-contacting latissimus dorsi muscle requires weeks 
of muscle preconditioning before transfer around the heart 
and provides only limited assistance in its present state 
of development antl has largely been abandoned. 
Non-blood-contacting biventricular support using 
DMVA has the following advantages: 
1. Rapid application through a small left anterior thor- 
cotomy without requiring cardiopulmonary bypass. 
2. No Hoodstream contact eliminates the need for antico- 
a-dation. 
3. Can lie used to provide circulatory support in the failing, 
fibrillating, and asystolic heart. 
4. The risks of hemorrhage and thromboembolism are 
reduced lierause bloodstream contact and the need for 
anticoagulation are eliminated. 
5. No blood contact and device application via a thora- 
cotomy insteacl of a meclian sternotomy may reduce 
infectious complications. 
6. Reducer1 healthcare costs in patients requiring mechani- 
cal support for refractory heart failure. 
7. DMVA can he used to  reverse entl-organ failure secontl- 
ary to refractory heart failure and identify patients who 
woidd 1)enefit from implantation of temporary or totally 
implantalde left ventricular arrest tlevices. 
DMVA can be rapidly applied to provide immediate 
hemodynamic stabilization. DMVA employs a contoured 
cup that attaches itself to the ventricular myorar- 
tlimn via a continuous vacuum at the apex of the cup. Once 
attached, positive ant1 negative pneumatic forces oper- 
ate on a diaphragm within the cup to “actuate’* both 
ventricles into respective systolic antl diastolic configu- 
rations (Fig I). Appropriate delivery of uniform positive 
and negative forces to the ventricles rapidly returns the 
failing, systolic. or fibrillating heart to its function as a 
ljlood pump. The apiral vaciiinn source seals the actuating 
cliaphragm to the myocardial surface, and, consequently. 
the device not only compresses the ventricles to create 
systole, hut also enhances cardiac filling by decompress- 
ing the ventricles into a diastolic configuration.9 
The massaging action of DMVA is controlled by a pneu- 
atic drive unit that has both pulsed volume and b u s -  
tained vacuum systems (Fig I). The vacuum system allows 
for device attachment and can he adjusted to the min- 
a1 degree of suction (usually -40 to -70 mm Hg) needed 
to maintain a constant diaphragm-to-epicarclium seal. 
The internal diameter in millimeters of each assist cup is 
identified by a numerical label. An appropriate cup size is 
one that approximates the greatest transverse diameter 
of the unassisted heart.9 Wrap-around Duramer (I< & L 
Technologies, Durham, NC) support cups currently un- 
der development eliminate the lifting and shearing vectors 
present in old silastic cups (Fig 1I).l6 
Once the need for DMVA has been established, the 
assist cup can rapidly be positioned through a small left 
anterior, sixth intercostal space thoracotomy (see Surgi- 
cal Technique). After the heart is adequately exposed, 
a general size is selected, and the device is positioned 
over the ventricular apex while set in a diastolic mode. 
The drive system’s continuous vacuum source causes 
the device to aspirate itself onto the heart. Once 
attached, the drive system is switched into an actuating 
mode, which cycles positive and negative forces from 
the pulsed volume source, resulting in ventricular 
systole and diastole. DMV4 application literally takes 
seconds after adequate exposure has been obtained .’ 
Operation of the current pump system is accon- 
plishecl with a computer that has memory, timer, and 
input/output functions. The computer interfaces with 
an operator panel. which allows the setting of assist rate 
(or synchronization to an R-wave trigger pulse), systolic 
duration, systolic volume, and diastolic pressure and 
monitors the systolic pressure within the diaphragm 
tlriveline (Fig II1).lf’ 
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Fig I. Schematic diagram of DMVA drive system and cup. 
The cup is shown actuating both ventricles into systolic 
(right) and diastolic configurations (left). (Reprinted with 
permissi0n.j) 
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Fig 11. The components of a DMVA heart cup. The wrap-around design 
contains a flexible diaphragm bonded circumferentially at  the base and apex 
of a semi-rigid housing. The apical port communicates with the space 
occupied by the ventricles. The side arm communicates with the space 
between the outer housing and inner diaphragm. (Reprinted with permis- 
sion. 5, 
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Fig 111. Volume-controlled driveline system control panel 
display. Note the ability to adjust assist rate, systolic dura- 
tion volume and pressure, the diastolic pressure, as well as 
the continuous apical suction. 
Application of DMVA Support in Select Patients 
With Refractory Cardiogenic Shock 
To date, we have used DMVA in five patients in cardio- 
genic shock. The etiologies of the cardiac failure were 
diverse and included idiopathic dilated cardiomyopa- 
thy (n = 2), massive myocardial infarction (n = 2), 
and viral myocarditis (n = 1). There were no device- 
related complications or deaths.’ The cardiac support 
cups were applied only in patients who were not 
candidates for blood-contacting ventricular assist de- 
vices. Duration of support ranged from 2 days to 3 
months. Two patients are long-term survivors (one 
bridge-to-transplant and one recovery from viral myo- 
carditis). Figure IV shows preparation for cardiopulmo- 
nary bypass before cardiac transplantation in a patient 
when the device was placed as a bridge. Figure V displays 
the systemic arterial and venous pressures before and 
during 45 hours of support in a DMVA recipient. 
The pathology of the hearts in the three patients who 
died showed encasement in a fibrinous epicardial 
peel, which appeared to provide a physiological buffer 
or lubricant preventing significant myocardial trauma. 
Fig IV. Before cardiac transplantation, cardiopulmonary bypass was instituted using standard 
cannulation techniques through a virgin sternotomy (left). Device removal was performed by 
cutting the sterile drivelines within the chest and removing the cup through the sternotomy 
(right). (Reprinted with permission from the Society of Thoracic S ~ r g e o n s . ~ )  
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Fig V. Systemic arterial and venous pressures before and 
during 45 hours of support in a DMVA recipient. Use of an 
intra-aortic balloon pump and all inotropic agents was dis- 
continued immediately after DMYA application. (Reprinted 
with permission from the Society of Thoracic  surgeon^.^) 
After 7.5 days of support in the patient who recovered 
from viral myocarditis, there was no clinical evidence of 
myocardial trauma. Before discharge, echocardiogra- 
phy and a rest and exercise multiple uptake gated 
acquisition scan showed complete return of normal 
cardiac functi0n.l 
Prolonged Circulatory Support During 
Ventricular Fibrillation 
In 1964, the first series of DMVA experiments involving 
successful circulatory support were performed on a dog 
during 8 hours of ventricular fibrillation (VF). At the 
time, this was the longest period of total circulatory 
support resulting in long-term s~rviva1. l~ Later in the 
mid-l960s, longer periods of total circulatory support 
were evaluated with a 50% survival reported in animals 
supported for 24 to 40 hours of VF.18 
Coogan, in the late 1960s, examined the possible 
traumatic effects of DMVA on the heart, with extensive 
histological evaluations performed on the organs of dogs 
surviving long term after support for 6 to 24 hours of 
VF. Studies were performed examining animals at 48 
hours (acute effects) and 3.5 to 20 months (chronic 
effects) after weaning from DMVA and restoration of 
normal sinus rhythm.19 At 48 hours, all hearts ap- 
peared histologically normal except for a variable 
degree of nontransmural ecchymosis on the endocardia1 
surface of the right ventricle near the pulmonary 
outflow tract. The chronic hearts also showed normal 
histology except for a small (<1 cm2) nontransmural 
scar in the same region of the right ventricle. The 
epicardial surfaces showed a third, nonconstrictive 
fibrinous layer. l8 The right ventricular pathology likely 
resulted from the overzealous application of pneumatic 
forces during early systolic actuation. These forces can 
be eliminated with proper adjustment of DMVA drive 
parameters, such as dampening of systolic pressure. 
Most investigators agree that the pathology seems nlini- 
mal when one realizes how poorly the fibrillating heart 
tolerates other methods of circulatory s ~ p p o r t . ~ > ~ ' - ~ ~  
More recently, we were able to provide total circula- 
tory support in a sheep for 7 days of W. The heart was 
subsequently defibrillated into sinus rhythm. During 
the period of support, no creatine kinase/myocardial 
band fraction was greater than 1%, suggesting that 
prolonged application of DMVA during VF does not 
result in serious myocardial injury. Additionally, renal 
function was preserved during the period of support, as 
evidenced by normal urine output, blood urea nitrogen, 
and creatinine levels. Histologically, the heart showed a 
fibrinous pericarditis with bruising limited to the outer 
1 mm of the epicardium and scattered foci of contrac- 
tion band necrosis of varying severity. Scanning elec- 
tron microscopy showed no evidence of cellular in- 
growth into the silicone rubber diaphragm. 
Neurologically, the 7-day support animal was intact 
with no evidence of cerebral lesions on neuropathologi- 
cal e~aminat ion.~ 
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SURGICAL TECHNIQUE 
1 After placement of an arterial line and pulmonary artery pressure catheter, the patient is 
positioned supine with the left hemithorax elevated by padding to approximately 30". DMVA cup 
application is made by exposing the heart via a left anterior thoracotomy through the sixth intercostal 
space. The pericardium is opened anterior to the phrenic nerve and the cup positioned over the 
ventricular apex, which results in self-attachment via the apical vacuum line (left). After assuring an 
adequate cup fit, the apical suction and drivelines are brought through separate stab incisions. A single 
chest tube is placed, and the chest is closed in a routine fashion (right). (Reprinted with permission 
from the Society of Thoracic  surgeon^.^) 
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Control Panel Maximization of Driveline 
Henodynamics 
The pneumatic driveline system for DMVA includes the 
following properties: 
1. 
2. 
3. 
4. 
Systolic and diastolic actuation must be separately 
controllable events. 
Systolic compression should be determined by a set 
volume of air delivered to the cup during the 
duration of systole. The peak pressure of this cycle 
should be monitored, but optimal systolic actuation 
is not a pressure-controlled event. The volume of air 
delivered during systolic actuation is determined by 
support cup size, inner compressing membrane com- 
pliance, myocardial compliance, ventricular after- 
load, and the desired cardiac output to be achieved. 
The volume of air delivered during systolic actuation 
of the cup (regardless of systolic duration) is the 
same volume of air that must be evacuated from the 
cup during systolic actuation (independent of dia- 
stolic duration). The rate of evacuation of air during 
diastolic actuation determines the negative pressure 
exerted on the heart to maximize diastolic filling of 
the ventricles. 
Finally, the pump is capable of both synchronous 
and asynchronous operation. 
After acute hernodynamic stabilization, systolic (+ 120 
to +130 mm Hg) and diastolic (-100 to -115 mm Hg) 
forces and flow rates can be adjusted to maximize 
hemodynamics. Cycle rates are generally set between 
80lmin (large hearts) to 120/min (smaller hearts). Ad- 
equate left ventricular emptying is generally achieved 
by systolic durations set to 44% of the DMVA cycle. 
This is important so as to minimize the potential for 
pulmonary edema, which may result from an abbrevi- 
ated systolic force emptying the right, but not the left, 
ventricle. To further help avoid this complication, 
pulmonary artery wedge pressures should be monitored 
in all DMVA patients. A progressive elevation in wedge 
pressure during support indicates the need for in- 
creased systolic duration.’ 
Potential Complications 
The potential for other complications may be minimized 
through preparation. A leak in the actuating diaphragm 
is easily detected by fluctuations in driveline and 
vacuum attachment pressures. Although such an event 
requires device replacement, initial hemodynamic stabi- 
lization can be maintained by increasing driving pres- 
sures. The possibility of a pneumothorax is prevented 
by placement of a chest tube at the time of initial 
thoracotomy. The pneumatic drive unit is an unlikely 
source of mechanical failure hut should be monitored 
closely as with any other device. For these reasons, an 
additional drive unit is available for emergency back-up 
at all times.9 
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